← Leaderboards
Margaret Haney
New York State Psychiatric Institute
$20,571,313
Attributed
$21,466,136
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$21,466,136 · 13
By mechanism
R01$17,303,113 · 7
P50$2,332,057 · 1
U54$899,741 · 1
M01$483,192 · 3
R21$448,033 · 1
Top collaborators
- Caroline A Arout2 shared
- Sachin Patel2 shared
Most similar at New York State Psychiatric Institute
Same institution · by research overlap
- Herbert David Kleber$7,837,431
- Suzette M Evans$16,643,423
- David J McDowell$1,498,011
- Sandra D. Comer$36,146,642
- Carl L. Hart$6,284,377
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchAbstinencePharmaceutical PreparationsRelapseLaboratoriesSelf AdministrationCannabisTreatment OutcomeCravingSmokerWithdrawalProceduresHuman SubjectInpatientsCannabinoidsTetrahydrocannabinolParticipantMarijuana SmokingFundingAgonistCocaineBasePlacebosDrug Screening /Evaluation
Grant awards (48)
Repeated Administration of Cannabis Varying in THC and CBD: Effects on Abuse Liability, Experimental Pain and Plasma Endocannabinoids$663,374
R01 · FY2023 · DA · contact PI
Repeated Administration of Cannabis Varying in THC and CBD: Effects on Abuse Liability, Experimental Pain and Plasma Endocannabinoids$678,240
R01 · FY2022 · DA · contact PI
Cannabis Relapse: Influence of Tobacco Cessation$555,643
R01 · FY2022 · DA · contact PI
Cannabis Relapse: Influence of Tobacco Cessation$554,156
R01 · FY2021 · DA · contact PI
Cannabis Relapse: Influence of Tobacco Cessation$543,590
R01 · FY2020 · DA · contact PI
Cannabis Relapse: Influence of Tobacco Cessation$542,992
R01 · FY2019 · DA · contact PI
Cannabis Relapse: Influence of Tobacco Cessation$528,716
R01 · FY2018 · DA · contact PI
Non-Metabolized Pregnenolone Derivatives:New Treatment for Cannabis Use Disorder$1,427,946
R01 · FY2017 · DA · contact PI
Non-Metabolized Pregnenolone Derivatives:New Treatment for Cannabis Use Disorder$1,649,677
R01 · FY2016 · DA · contact PI
Project 1: Laboratory: Pharmacotherapies for Cannabis Use Disorders$471,478
U54 · FY2015 · DA · contact PI
Cycooxygenase-2 Inhibition for Cannabis Withdrawal and Relapse$201,718
R21 · FY2015 · DA · contact PI
Marijuana Relapse: Influence of Tobacco Cessation and Varenicline$503,778
R01 · FY2014 · DA · contact PI
Project 1: Laboratory: Pharmacotherapies for Cannabis Use Disorders$428,263
U54 · FY2014 · DA · contact PI
Cycooxygenase-2 Inhibition for Cannabis Withdrawal and Relapse$246,315
R21 · FY2014 · DA · contact PI
Marijuana Relapse: Influence of Tobacco Cessation and Varenicline$494,547
R01 · FY2013 · DA · contact PI
Marijuana Relapse: Influence of Tobacco Cessation and Varenicline$516,716
R01 · FY2012 · DA · contact PI
Modafinil and DRD4 Genotype in a Human Laboratory Model of Cocaine Relapse$559,888
R01 · FY2011 · DA · contact PI
Marijuana Relapse: Influence of Tobacco Cessation and Varenicline$506,259
R01 · FY2011 · DA · contact PI
Modafinil and DRD4 Genotype in a Human Laboratory Model of Cocaine Relapse$546,204
R01 · FY2010 · DA · contact PI
Marijuana Relapse: Influence of Tobacco Cessation and Varenicline$498,587
R01 · FY2010 · DA · contact PI
Modafinil and DRD4 Genotype in a Human Laboratory Model of Cocaine Relapse$538,028
R01 · FY2009 · DA · contact PI
Modafinil and DRD4 Genotype in a Human Laboratory Model of Cocaine Relapse$527,283
R01 · FY2008 · DA · contact PI
Medication Development for Marijuana Relapse$468,829
R01 · FY2008 · DA · contact PI
Pharmacological Treatment of Marijuana Dependence$394,017
P50 · FY2008 · DA · contact PI
Medication Development for Marijuana Relapse$483,011
R01 · FY2007 · DA · contact PI
Pharmacological Treatment of Marijuana Dependence$455,931
P50 · FY2007 · DA · contact PI
Medication Development for Marijuana Relapse$493,898
R01 · FY2006 · DA · contact PI
Pharmacological Treatment of Marijuana Dependence$289,416
P50 · FY2006 · DA · contact PI
Medication Development for Marijuana Relapse$524,739
R01 · FY2005 · DA
Pharmacological Treatment of Marijuana Dependence$288,355
P50 · FY2005 · DA
VACCINE STUDY$149,350
M01 · FY2005 · RR
BACLOFEN AND COCAINE$43,869
M01 · FY2005 · RR
THE DISCRIMINATIVE STIMULUS EFFECTS OF COCAINE$2,258
M01 · FY2005 · RR
Medication Development for Marijuana Relapse$519,312
R01 · FY2004 · DA
Pharmacological Treatment of Marijuana Dependence$276,740
P50 · FY2004 · DA
Gabapentin and Cocaine$135,526
M01 · FY2004 · RR
Vaccine Study$113,864
M01 · FY2004 · RR
Baclofen and Cocaine$38,325
M01 · FY2004 · RR
NOVEL COCAINE PHARMACOTHERAPIES: LAB STUDIES$545,915
R01 · FY2003 · DA
NOVEL COCAINE PHARMACOTHERAPIES: LAB STUDIES$586,839
R01 · FY2002 · DA
THC AND MARIJUANA--EFFECTS IN INDIVIDUALS WITH HIV/AIDS$469,454
R01 · FY2002 · DA
PHARMACOLOGICAL TREATMENT OF MARIJUANA DEPENDENCE$0
P50 · FY2002 · DA
NOVEL COCAINE PHARMACOTHERAPIES: LAB STUDIES$503,020
R01 · FY2001 · DA
THC AND MARIJUANA--EFFECTS IN INDIVIDUALS WITH HIV/AIDS$455,784
R01 · FY2001 · DA
PHARMACOLOGICAL TREATMENT OF MARIJUANA DEPENDENCE$0
P50 · FY2001 · DA
THC AND MARIJUANA--EFFECTS IN INDIVIDUALS WITH HIV/AIDS$416,688
R01 · FY2000 · DA
PHARMACOLOGICAL TREATMENT OF MARIJUANA DEPENDENCE$313,799
P50 · FY2000 · DA
PHARMACOLOGICAL TREATMENT OF MARIJUANA DEPENDENCE$313,799
P50 · FY2000 · DA